Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:11 PM
Ignite Modification Date:
2025-12-24 @ 9:11 PM
NCT ID:
NCT03744104
Eligibility Criteria:
Inclusion Criteria:
* Over the age of three years,healthy population
* Subjects/ (and the guardian) informed consent, voluntarily participated and signed the informed consent form, with the ability to use thermometers, scales and to fill in diary cards as required
* To comply with the requirements of clinical trial program
* Temperature≤37.0℃ on day of enrollment
Exclusion Criteria:
* A history of influenza virus infection or suspected infection Abnormal blood routine, blood biochemistry and urine routine examination indexes in last three months
* Any prior administration of influenza vaccine in last six months
* Allergy to any component in the vaccine, especially for egg allergy
* Allergy history of any previous vaccination or drug
* Acute episodes of chronic illness or acute illness on the day of vaccination
* Received a live vaccine within fourteen days prior to receiving the vaccine, or received a subunit or inactivated vaccine within seven days
* Congenital or acquired immune deficiencies, or treatment with immunosuppressive agents, such as long-term treatment with systemic corticosteroids
* Suffering from severe chronic diseases (such as Down's syndrome, diabetes, sicklemia or neurological disorders, Green's Barre syndrome)
* Asthma, required urgent treatment in last two years
* The blood products were received prior to the acceptance of the vaccine
* Known or suspected of respiratory disease, acute infection or chronic disease active period, HIV infection, cardiovascular disease, severe hypertension, malignant tumor during treatment, skin diseases
* History of epilepsy, convulsions, or a family history of psychosis
* Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities), or obvious bruising or coagulopathy
* Plan to move or leave the area for an extended period of time before the end of the study
* Under anti-tb treatment
* Any prior administration of other research medicine/vaccine in last one month
* Women are pregnant or in the near future planned pregnancy or pregnancy test positive
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
3 Years
Study:
NCT03744104
Study Brief:
Protocol Section:
NCT03744104